Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses

[1]  V. Anttila,et al.  Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. , 2017, The Lancet. Infectious diseases.

[2]  S. Levidiotou,et al.  Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study , 2017, PloS one.

[3]  A. Delgado,et al.  Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals , 2017, BMC Infectious Diseases.

[4]  N. Khanafer,et al.  Factors associated with Clostridium difficile infection: A nested case-control study in a three year prospective cohort. , 2017, Anaerobe.

[5]  A. Rodloff,et al.  Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis , 2016, Infectious Diseases and Therapy.

[6]  M. Wilcox,et al.  Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013. , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  M. Wilcox,et al.  Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. , 2015, The Journal of antimicrobial chemotherapy.

[8]  D. Gerding,et al.  NAP1 strain type predicts outcomes from Clostridium difficile infection. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. P. Bauer,et al.  European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  Mark A. Miller,et al.  Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  O. Dekkers,et al.  All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Mark A. Miller,et al.  Effect of Age on Treatment Outcomes in Clostridium difficile Infection , 2013, Journal of the American Geriatrics Society.

[13]  K. Sepkowitz,et al.  Hospital-Onset Clostridium difficile Infection Rates in Persons with Cancer or Hematopoietic Stem Cell Transplant: A C3IC Network Report , 2012, Infection Control & Hospital Epidemiology.

[14]  T. Louie,et al.  Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  D. Gerding,et al.  Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Derrick W. Crook,et al.  Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Falagas,et al.  Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. , 2012, International journal of antimicrobial agents.

[18]  R. Britton,et al.  Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. , 2012, Trends in microbiology.

[19]  D. Crook,et al.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. , 2012, The Lancet. Infectious diseases.

[20]  F. Allerberger,et al.  Use of different molecular typing methods for the study of heterogeneity within Clostridium difficile toxinotypes V and III. , 2011, Journal of medical microbiology.

[21]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[22]  J. Brazier,et al.  PCR Targeted to the 16S-23S rRNA Gene Intergenic Spacer Region ofClostridium difficile and Construction of a Library Consisting of 116 Different PCR Ribotypes , 1999, Journal of Clinical Microbiology.

[23]  C. Kelly.  Can we identify patients at high risk of recurrent Clostridium difficile infection? , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.